| | RF + PJIA (n = 7 [14%]) | RF − PJIA (n = 9 [18%]) | OJIA (n = 33 [67%]) | p-value |
|---|
Active disease | 0 | 0 | 1 (3%)b | 0.79 |
Inactive disease | 0 | 0 | 2 (9%)c | 0.61 |
CRM | 6 (86%) | 4 (44%) | 5 (15%) | < 0.01e |
bDMARDs + csDMARDs | 3 (43%) | 2 (22%) | 1 (3%) | - |
bDMARDs | 3 (43%) | 2 (22%) | 0 (0%) | - |
bDMARDs + csDMARDs + GC | 0 | 0 | 1 (3%) | - |
No medication | 0 | 0 | 3 (9%)d | - |
CR | 1 (14%)a | 5 (56%) | 22 (67%) | < 0.05f |
- Data are presented as n (%), unless otherwise indicated
- ACPA anti-cyclic citrullinated peptide antibody, bDMARD biological disease-modifying antirheumatic drug, CR clinical remission off medication, CRM clinical remission on medication, csDMARD conventional synthetic disease-modifying antirheumatic drug, GC glucocorticoid, OJIA oligoarticular juvenile idiopathic arthritis, PJIA polyarticular juvenile idiopathic arthritis, RF rheumatoid factor
- aACPA-negative case
- bOne patient with OJIA presented with active uveitis and had active disease
- cIn both cases, bDMARDs were introduced after flare on csDMARDs monotherapy and ID was achieved with a combination of bDMARDs and csDMARDs
- d < 12 months after discontinuation of all medications
- eRF + PJIA versus RF − PJIA, p-value 0.22. RF + PJIA versus OJIA, p-value < 0.01. RF − PJIA versus OJIA, p-value 0.15
- fRF + PJIA versus RF − PJIA, p-value 0.23. RF + PJIA versus OJIA, p-value < 0.05. RF − PJIA versus OJIA, p-value 0.82
